| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 10,328 | 6,121 | ||
| General and administrative | 6,478 | 5,671 | ||
| Total operating expenses | 16,806 | 11,792 | ||
| Net operating loss | -16,806 | -11,792 | ||
| Interest income | 1,017 | 954 | ||
| Other income (expense), net | -15 | -9 | ||
| Net loss | -15,804 | -10,847 | ||
| Earnings per share, basic | -0.4 | -0.27 | ||
| Earnings per share, diluted | -0.4 | -0.27 | ||
| Weighted average number of shares outstanding, basic | 39,741,404 | 39,572,177 | ||
| Weighted average number of shares outstanding, diluted | 39,741,404 | 39,572,177 | ||
TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC. (TENX)